Susan Zweizig to Drug Resistance, Neoplasm
This is a "connection" page, showing publications Susan Zweizig has written about Drug Resistance, Neoplasm.
Connection Strength
0.127
-
Brewer CA, Blessing JA, Nagourney RA, McMeekin DS, Lele S, Zweizig SL. Cisplatin plus gemcitabine in previously treated squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol. 2006 Feb; 100(2):385-8.
Score: 0.056
-
Herzog TJ, Liao JB, Finkelstein K, Willmott L, Duan W, Moroney JW, Buscema J, Campbell-Simms K, Yue Y, Zweizig S, Liu J, Wang X, Zang RY, Yin R, O'Malley DM, Wu L. An open-label randomized active-controlled phase II clinical study to assess the efficacy and safety of afuresertib plus paclitaxel versus paclitaxel in patients with platinum-resistant ovarian cancer (PROFECTA-II/GOG-3044). Gynecol Oncol. 2025 Mar; 194:145-152.
Score: 0.053
-
De Geest K, Blessing JA, Morris RT, Yamada SD, Monk BJ, Zweizig SL, Matei D, Muller CY, Richards WE. Phase II clinical trial of ixabepilone in patients with recurrent or persistent platinum- and taxane-resistant ovarian or primary peritoneal cancer: a gynecologic oncology group study. J Clin Oncol. 2010 Jan 01; 28(1):149-53.
Score: 0.018